-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Brain metastasis (BM) is one of the most common metastatic sites of primary lung cancer.
Brain metastasis (BM) is one of the most common metastatic sites of primary lung cancer.
The study used the NLST database to include 1502 patients diagnosed with lung cancer from 2002 to 2009, and followed up to observe the occurrence of BM.
The study used the NLST database to include 1502 patients diagnosed with lung cancer from 2002 to 2009, and followed up to observe the occurrence of BM.
research summary
Compared with lung cancer patients detected by other methods, the incidence of BM in lung cancer patients found in LDCT screening was lower at 3 years (6.
Compared with lung cancer patients detected by other methods, the incidence of BM in lung cancer patients found in LDCT screening was lower at 3 years (6.
Risk of BM in different groups1
Sensitivity analysis found that compared with chest X-ray, LDCT can reduce the risk of BM (HR = 0.
In summary, based on large-scale population studies, low-dose CT (LDCT) screening for early detection of primary lung cancer (PLC) can reduce the risk of brain metastasis (BM) after the diagnosis of PLC.
Original source:
Su CC, Wu JT, Neal JW, et al.
Su CC, Wu JT, Neal JW, et al.
Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis, Journal of Thoracic Oncology (2021), doi: https://doi.
org/10.
1016/ j.
jtho.
2021.
05.
010.
Leave a message here
